Lv6
2730 积分 2025-08-24 加入
Patient-Reported Outcomes and Time to Symptomatic Progression from Papillon: Amivantamab Plus Chemotherapy vs Chemotherapy as First-Line Treatment of Egfr Exon 20 Insertion-Mutated Advanced Nsclc
30天前
已完结
Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated EGFR -mutated non-small-cell lung cancer
30天前
已完结
FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)
30天前
已完结
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis
30天前
已完结
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC
30天前
已完结
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
1个月前
已完结
Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC
1个月前
已完结
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
1个月前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
1个月前
已完结
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
1个月前
已完结